Nasdaq Moves to Delist NeuroSense Over $35M Market Value Shortfall; Company to Appeal
NRSN is trading near its 52-week low of $3.82 (5.5% above the low).
Summary
Nasdaq issued a delisting determination after NeuroSense missed the $35M minimum market value requirement by September 29. The company will appeal and seek up to 180 more days, while confirming it has regained the $1.00 minimum bid price rule.
Key Events · Legal and Risk Events · NRSN
-
Nasdaq Delisting Determination Received
On October 1, 2026, Nasdaq Staff determined that NeuroSense failed to regain compliance with the $35M minimum market value of listed securities (MVLS) requirement by the September 29, 2026 deadline, triggering delisting of ordinary shares and warrants unless appealed.
-
Appeal to Nasdaq Hearings Panel
The company intends to timely request a hearing, which stays suspension and Form 25-NSE filing. The Panel may grant up to 180 days from the Staff Determination date for the company to regain compliance.
-
Bid Price Compliance Regained
Following the 1-for-20 reverse split, the closing bid price held at or above $1.00 for 10 consecutive business days (September 15-28, 2026), and Nasdaq confirmed the minimum bid price matter is now closed.
-
Financial Distress Context
The delisting determination follows the September 25, 2026 disclosure of only $0.2M in cash and a going concern warning, underscoring the company's precarious financial position.
Analysis · NRSN · Life Sciences
On October 1, 2026, Nasdaq formally determined that NeuroSense had not regained compliance with the $35 million minimum market value requirement by the September 29 deadline, setting in motion a delisting process for both ordinary shares and warrants. The company plans to appeal to a Nasdaq Hearings Panel, which could allow up to 180 additional days to remedy the deficiency. This development comes just days after NeuroSense disclosed only $0.2 million in cash and a going concern warning, and it follows the 1-for-20 reverse split that restored bid price compliance but failed to lift market value above the threshold. While the appeal stays delisting during the process, there is no guarantee the Panel will grant an exception.
How filings like this one have moved
In the 30 days to Oct 24, 2026, 37.1% of the 994 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $3.82 to $26.64. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.